Evolus, Inc. (EOLS) stock
Close on Nov 17, 2026Market cap $441.88MP/E –Yield –
Earnings
Evolus's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of Evolus's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Mar 2, 2027Expected | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 4, 2026after the close | $78.00M | +13.0% | -$0.19 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 5, 2026during market hours | $84.10M | +21.2% | – | Release |
| Q1 FY2026ended Mar 31, 2026 | May 4, 2026during market hours | $73.10M | +6.7% | – | Release |
| Q4 FY2025ended Dec 31, 2025 | Mar 3, 2026during market hours | $90.30M | +14.3% | $0.00 | Release |
| Q3 FY2025ended Sep 30, 2025 | Nov 5, 2025during market hours | $69.00M | +12.9% | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Aug 5, 2025during market hours | $69.40M | +3.7% | -$0.27 | Release |
| Q1 FY2025ended Mar 31, 2025 | May 7, 2025during market hours | $68.50M | +15.5% | -$0.30 | Release |
| Q4 FY2024ended Dec 31, 2024 | Mar 4, 2025during market hours | $79.00M | +29.5% | -$0.11 | Release |
| Q3 FY2024ended Sep 30, 2024 | Nov 6, 2024during market hours | $61.10M | +22.2% | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024during market hours | $66.90M | +35.7% | -$0.18 | Release |
| Q1 FY2024ended Mar 31, 2024 | May 7, 2024during market hours | $59.30M | +42.2% | -$0.22 | Release |
| Q4 FY2023ended Dec 31, 2023 | Mar 7, 2024during market hours | $61.00M | +39.9% | -$0.21 | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 7, 2023during market hours | $50.00M | +47.5% | -$0.30 | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 2, 2023during market hours | $49.30M | +32.5% | -$0.32 | Release |
| Q1 FY2023ended Mar 31, 2023 | May 9, 2023during market hours | $41.70M | +23.0% | -$0.26 | Release |
| Q4 FY2022ended Dec 31, 2022 | Mar 8, 2023during market hours | $43.60M | +25.6% | -$0.23 | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 8, 2022during market hours | $33.90M | +27.0% | -$0.36 | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 2, 2022before the open | $37.20M | – | -$0.42 | Release |
| Q1 FY2022ended Mar 31, 2022 | May 10, 2022during market hours | $33.90M | – | -$0.31 | Release |
| Q4 FY2021ended Dec 31, 2021 | Mar 3, 2022during market hours | $34.70M | – | -$0.33 | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 2, 2021before the open | $26.70M | – | -$0.35 | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 4, 2021during market hours | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | Apr 26, 2021during market hours | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Feb 23, 2021before the open | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Oct 29, 2020during market hours | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
Evolus's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| total net revenuesGAAP | FY2026 | $330.00M – $337.00M | – | New | Nov 4, 2026 |
| total net revenues | FY2026 | $330.00M – $337.00M | $327.00M – $337.00M | Raised | Aug 5, 2026 |
| Total net revenues | FY2026 | $327.00M – $337.00M | – | New | Mar 3, 2026 |
| adjusted gross profit marginnon-GAAP | FY2026 | 67% – 67.5% | 65.5% – 67% | Raised | Nov 4, 2026 |
| adjusted gross profit marginnon-GAAP | FY2026 | 67% – 67.5% | 65.5% – 67% | Raised | Aug 5, 2026 |
| contribute 10% to 12% of total revenue | FY2026 | 10% – 12% | – | New | Mar 3, 2026 |
| Evolysse ® and Estyme ® injectable HA gels to contribute 10% to 12% of total revenue | FY2026 | 10% – 12% | – | New | Aug 5, 2026 |
| non-GAAP operating expensesnon-GAAP | FY2026 | $210.00M – $213.00M | $210.00M – $216.00M | Lowered | Nov 4, 2026 |
| non-GAAP operating expensesnon-GAAP | FY2026 | $212.00M – $216.00M | $210.00M – $216.00M | Raised | Aug 5, 2026 |
| compound annual growth rate | FY2028 | +27% | – | New | May 7, 2025 |
| total net revenueGAAP | FY2028 | $450.00M – $500.00M | $700.00M | Lowered | Nov 4, 2026 |
| total net revenue | FY2028 | $450.00M – $500.00M | $450.00M – $500.00M | Reaffirmed | Aug 5, 2026 |
| total net revenue | FY2028 | $450.00M – $500.00M | $700.00M | Lowered | Mar 3, 2026 |
| non-GAAP operating income marginsnon-GAAP | FY2028 | 13% – 15% | 20% | Lowered | Jan 9, 2026 |
| non-GAAP operating income marginsnon-GAAP | FY2028 | 20% | 20% | Reaffirmed | Aug 5, 2025 |
| operating margins | FY2028 | 20% | – | New | Nov 6, 2024 |
| Adjusted EBITDA marginsnon-GAAP | FY2028 | 13% – 15% | 13% – 15% | Reaffirmed | Nov 4, 2026 |
| Adjusted EBITDA marginsnon-GAAP | FY2028 | 13% – 15% | – | New | Aug 5, 2026 |
| Adjusted EBITDA marginsnon-GAAP | FY2028 | 13% – 15% | – | New | May 4, 2026 |
Guidance vs results
The last range Evolus gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $295.00M – $305.00M | $297.20MΣ4Q | Within range |
| FY2025 | Revenue growth | +11% – +15% | +11.6%Σ4Q | Within range |
Guidance history
Every forecast Evolus put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 4, 2026 | Adjusted EBITDA margins | FY2028 | 13% – 15% | Reaffirmed |
| Nov 4, 2026 | adjusted gross profit margin | FY2026 | 67% – 67.5% | Raised |
| Nov 4, 2026 | non-GAAP operating expenses | FY2026 | $210.00M – $213.00M | Lowered |
| Nov 4, 2026 | total net revenues | FY2026 | $330.00M – $337.00M | New |
| Nov 4, 2026 | total net revenue | FY2028 | $450.00M – $500.00M | Lowered |
| Aug 5, 2026 | Adjusted EBITDA margins | FY2028 | 13% – 15% | New |
| Aug 5, 2026 | adjusted gross profit margin | FY2026 | 67% – 67.5% | Raised |
| Aug 5, 2026 | Evolysse ® and Estyme ® injectable HA gels to contribute 10% to 12% of total revenue | FY2026 | 10% – 12% | New |
| Aug 5, 2026 | non-GAAP operating expenses | FY2026 | $212.00M – $216.00M | Raised |
| Aug 5, 2026 | total net revenues | FY2026 | $330.00M – $337.00M | Raised |
| Aug 5, 2026 | total net revenue | FY2028 | $450.00M – $500.00M | Reaffirmed |
| May 4, 2026 | Adjusted gross profit margin | FY2026 | 65.5% – 67% | New |
| May 4, 2026 | Non-GAAP operating expenses | FY2026 | $210.00M – $216.00M | New |
| May 4, 2026 | Adjusted EBITDA margins | FY2028 | 13% – 15% | New |
| May 4, 2026 | Total net revenues | FY2026 | $327.00M – $337.00M | Reaffirmed |
| May 4, 2026 | total net revenue | FY2028 | $450.00M – $500.00M | Reaffirmed |
| Mar 3, 2026 | adjusted EBITDA margins | FY2028 | 13% – 15% | New |
| Mar 3, 2026 | adjusted gross profit margin | FY2026 | 65.5% – 67% | New |
| Mar 3, 2026 | contribute 10% to 12% of total revenue | FY2026 | 10% – 12% | New |
| Mar 3, 2026 | Non-GAAP operating expenses | FY2026 | $210.00M – $216.00M | New |
| Mar 3, 2026 | Total net revenues | FY2026 | $327.00M – $337.00M | New |
| Mar 3, 2026 | total net revenue | FY2028 | $450.00M – $500.00M | Lowered |
| Jan 9, 2026 | non-GAAP operating income margins | FY2028 | 13% – 15% | Lowered |
| Jan 9, 2026 | Total net revenues | FY2026 | $327.00M – $337.00M | New |
| Jan 9, 2026 | total net revenue | FY2028 | $450.00M – $500.00M | Lowered |
| Nov 5, 2025 | positive non-GAAP operating income | Q4 FY2025 | $5.00M – $7.00M | New |
| Nov 5, 2025 | non-GAAP operating income margins | FY2028 | 20% | New |
| Nov 5, 2025 | non-GAAP operating expenses | FY2025 | $208.00M – $213.00M | New |
| Nov 5, 2025 | Total net revenues growth | FY2025 | +11% – +15% | New |
| Nov 5, 2025 | Total net revenues | FY2025 | $295.00M – $305.00M | New |
| Nov 5, 2025 | Total net revenue | FY2028 | $700.00M | New |
| Aug 5, 2025 | non-GAAP operating income margins | FY2028 | 20% | Reaffirmed |
| Aug 5, 2025 | non-GAAP operating expenses | FY2025 | $208.00M – $213.00M | Lowered |
| Aug 5, 2025 | growth over 2024 results | FY2025 | +11% – +15% | Lowered |
| Aug 5, 2025 | Total net revenues | FY2025 | $295.00M – $305.00M | Lowered |
| Aug 5, 2025 | Total net revenue | FY2028 | $700.00M | Reaffirmed |
| May 7, 2025 | non-GAAP operating income margins | FY2028 | 20% | Reaffirmed |
| May 7, 2025 | non-GAAP operating expenses | FY2025 | $230.00M – $240.00M | Reaffirmed |
| May 7, 2025 | revenue growth | FY2025 | +30% – +33% | Reaffirmed |
| May 7, 2025 | Total net revenues | FY2025 | $345.00M – $355.00M | Reaffirmed |
| May 7, 2025 | compound annual growth rate | FY2028 | +27% | New |
| May 7, 2025 | Total net revenue | FY2028 | $700.00M | Reaffirmed |
| Mar 4, 2025 | non-GAAP operating income margins | FY2028 | 20% | Reaffirmed |
| Mar 4, 2025 | Evolysse™ and Estyme ® injectable hyaluronic acid (HA) gels anticipated contribution to total revenue | FY2025 | 8% – 10% | Reaffirmed |
| Mar 4, 2025 | Non-GAAP operating expenses | FY2025 | $230.00M – $240.00M | Reaffirmed |
| Mar 4, 2025 | Total net revenues | FY2025 | $345.00M – $355.00M | Reaffirmed |
| Mar 4, 2025 | total net revenue | FY2028 | $700.00M | Reaffirmed |
| Jan 21, 2025 | non-GAAP operating income margin | FY2028 | 20% | New |
| Jan 21, 2025 | contribute | FY2025 | 8% – 10% | New |
| Jan 21, 2025 | Non-GAAP operating expenses | FY2025 | $230.00M – $240.00M | New |
| Jan 21, 2025 | growth from preliminary 2024 results | FY2025 | +30% – +33% | New |
| Jan 21, 2025 | Total net revenues | FY2025 | $345.00M – $355.00M | New |
| Jan 21, 2025 | net revenue | FY2028 | $700.00M | Reaffirmed |
| Nov 6, 2024 | adjusted gross profit margin | FY2024 | 68% – 71% | Reaffirmed |
| Nov 6, 2024 | operating margins | FY2028 | 20% | New |
| Nov 6, 2024 | non-GAAP operating expenses | FY2024 | $185.00M – $190.00M | Reaffirmed |
| Nov 6, 2024 | year-over-year growth | FY2024 | +29% – +32% | New |
| Nov 6, 2024 | full year total net revenue | FY2024 | $260.00M – $266.00M | Lowered |
| Nov 6, 2024 | total net revenue | FY2028 | $700.00M | Reaffirmed |
| Jul 31, 2024 | adjusted gross profit margin | FY2024 | 68% – 71% | Reaffirmed |
| Jul 31, 2024 | non-GAAP operating expenses | FY2024 | $185.00M – $190.00M | Reaffirmed |
| Jul 31, 2024 | total net revenues | FY2024 | $260.00M – $270.00M | Raised |
| May 7, 2024 | adjusted gross profit margin | FY2024 | 68% – 71% | Reaffirmed |
| May 7, 2024 | non-GAAP operating expenses | FY2024 | $185.00M – $190.00M | Reaffirmed |
| May 7, 2024 | total net revenues | FY2024 | $255.00M – $265.00M | Reaffirmed |
| Mar 7, 2024 | adjusted gross profit margin | FY2024 | 68% – 71% | New |
| Mar 7, 2024 | non-GAAP operating expenses | FY2024 | $185.00M – $190.00M | New |
| Mar 7, 2024 | total net revenues | FY2024 | $255.00M – $265.00M | New |
| Nov 7, 2023 | adjusted gross profit margin | FY2023 | 68% – 71% | Reaffirmed |
| Nov 7, 2023 | full-year non-GAAP operating expenses | FY2023 | $153.00M – $158.00M | Reaffirmed |
| Nov 7, 2023 | total net revenues | FY2023 | $194.00M – $198.00M | Raised |
| Nov 7, 2023 | total net revenue | FY2028 | $700.00M | Raised |
| Aug 2, 2023 | adjusted gross profit margin | FY2023 | 68% – 71% | Reaffirmed |
| Aug 2, 2023 | non-GAAP operating expenses | FY2023 | $153.00M – $158.00M | Reaffirmed |
| Aug 2, 2023 | total net revenues | FY2023 | $185.00M – $195.00M | Raised |
| Aug 2, 2023 | total net revenue | FY2028 | $700.00M | Reaffirmed |
| May 9, 2023 | adjusted gross profit margin | FY2023 | 68% – 71% | Reaffirmed |
| May 9, 2023 | non-GAAP operating expenses | FY2023 | $153.00M – $158.00M | Raised |
| May 9, 2023 | total net revenues | FY2023 | $180.00M – $190.00M | New |
| May 9, 2023 | total net revenue | FY2028 | $700.00M | New |
| Mar 8, 2023 | adjusted gross profit margin | FY2023 | 68% – 71% | New |
| Mar 8, 2023 | non-GAAP operating expenses | FY2023 | $145.00M – $150.00M | New |
| Mar 8, 2023 | total net revenues | FY2023 | $180.00M – $190.00M | New |
| Mar 8, 2023 | total net revenue | FY2028 | $500.00M | New |
| Nov 8, 2022 | adjusted gross profit margin | Q4 FY2022 | 68% – 71% | Reaffirmed |
| Nov 8, 2022 | adjusted gross profit margin | FY2022 | 58% – 61% | Reaffirmed |
| Nov 8, 2022 | non-GAAP operating expenses | FY2022 | $135.00M – $140.00M | Reaffirmed |
| Nov 8, 2022 | sales | FY2022 | $143.00M – $150.00M | Reaffirmed |
| Aug 2, 2022 | adjusted gross profit margin | Q4 FY2022 | 68% – 71% | Reaffirmed |
| Aug 2, 2022 | adjusted gross profit margin | FY2022 | 58% – 61% | Reaffirmed |
| Aug 2, 2022 | non-GAAP operating expenses | FY2022 | $135.00M – $140.00M | Reaffirmed |
| Aug 2, 2022 | sales | FY2022 | $143.00M – $150.00M | Reaffirmed |
| May 10, 2022 | adjusted gross profit margin | Q4 FY2022 | 68% – 71% | Reaffirmed |
| May 10, 2022 | adjusted gross profit margin | FY2022 | 58% – 61% | Reaffirmed |
| May 10, 2022 | non-GAAP operating expenses | FY2022 | $135.00M – $140.00M | Reaffirmed |
| May 10, 2022 | sales | FY2022 | $143.00M – $150.00M | Reaffirmed |
| Mar 3, 2022 | adjusted gross profit margin | FY2022 | 58% – 61% | New |
| Mar 3, 2022 | adjusted gross profit margin | Q4 FY2022 | 68% – 71% | New |
| Mar 3, 2022 | Non-GAAP operating expenses | FY2022 | $135.00M – $140.00M | New |
| Mar 3, 2022 | total net revenues | FY2022 | $143.00M – $150.00M | New |
| Nov 2, 2021 | adjusted gross profit margin target | FY2021 | 54% – 57% | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases Evolus filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Results
- Update
- Update
- Results
- Results
- Results
- Results
- Update
- Results
- Update
- Results
- Update
- Results
- Results
See a number that looks wrong?